Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All AIM ImmunoTech Inc. filings on SEC EDGAR ↗
AIM ImmunoTech reported a net loss of $9.95 million for the nine months ended September 30, 2026, compared to $9.78 million in the prior year. The company significantly strengthened its balance sheet through equity offerings and warrant exercises, increasing total assets to $9.75 million and achieving a positive stockholders' equity of $7.08 million.
AIM ImmunoTech Inc. has released a new corporate presentation titled 'The Ampligen Opportunity' along with a corresponding press release. The presentation outlines the company's strategic objectives and the clinical potential of its lead drug candidate, Ampligen, particularly in treating pancreatic cancer.
AIM ImmunoTech Debt Financing Update with Streeterville Capital, LLC
AIM ImmunoTech entered into exchange agreements with Streeterville Capital to convert approximately $400,000 of an existing November 2025 promissory note into 1,749,434 shares of common stock. The conversion was executed at an average price of approximately $0.228 per share following prior stockholder approval for the debt satisfaction.